 |
 Video: What is a Stock Split?
|
|
|
| Biocept is a molecular oncology diagnostics company that develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid. Co. has commercialized its CNSide and Target Selector assays for detecting and characterizing various different carcinomas derived from epithelial cells of solid organs such as: breast cancer, non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. In addition, Co. has launched RT-PCR Coronavirus testing at its laboratory. According to our BIOC split history records, Biocept has had 3 splits. | |
|
Biocept (BIOC) has 3 splits in our BIOC split history database. The first split for BIOC took place on September 29, 2016. This was a 1 for 3 reverse split, meaning for each 3 shares of BIOC owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 333.333333333333 share position following the split. BIOC's second split took place on July 10, 2018. This was a 1 for 30 reverse split, meaning for each 30 shares of BIOC owned pre-split, the shareholder now owned 1 share. For example, a 333.333333333333 share position pre-split, became a 11.1111111111111 share position following the split. BIOC's third split took place on September 08, 2020. This was a 1 for 10 reverse split, meaning for each 10 shares of BIOC owned pre-split, the shareholder now owned 1 share. For example, a 11.1111111111111 share position pre-split, became a 1.11111111111111 share position following the split.
When a company such as Biocept conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the BIOC split history from start to finish, an original position size of 1000 shares would have turned into 1.11111111111111 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Biocept shares, starting with a $10,000 purchase of BIOC, presented on a split-history-adjusted basis factoring in the complete BIOC split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
02/05/2014 |
|
| End date: |
01/30/2023 |
|
| Start price/share: |
$8,460.00 |
|
| End price/share: |
$0.55 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-99.99% |
|
| Average Annual Total Return: |
-65.79% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$0.65 |
|
| Years: |
8.99 |
|
|
|
| Date |
Ratio |
| 09/29/2016 | 1 for 3 | | 07/10/2018 | 1 for 30 | | 09/08/2020 | 1 for 10 |
|
|
Free BIOC Email Alerts:
